

REMARKS

Upon entry of the foregoing amendments, claims 1-8, 18, 56, and 57 will be presently pending. Claims 1, 2, 6, and 18 have been amended. Claims 26-30, 39-55, and 58-66 have been cancelled without prejudice. Applicants note that claim 57, through an editorial oversight, was incorrectly presented in the Amendment of April 13, 2009. Claim 57 is correctly presented in the present Amendment, and recites a claim identical to that submitted in the Amendment of December 4, 2008. No new claims have been added. Applicants reserve the right to pursue any cancelled subject matter in a continuing or divisional application.

As recommended by the Examiner in the teleconference with counsel on June 30, 2009, claim 1 has been amended to recite that R³ and R⁴ may each independently be H. Support for this amendment is provided at least by claim 4 as originally filed. Claim 2 has been amended to recite that R⁵ may be a C₁-C₁₀ alkynyl. Support for this amendment is provided at least by the definition of R⁵ as recited in claim 1 as originally filed. Claim 6 has been amended to correct for a minor typographical error; namely, amending “CH₃” to “-CH₃.“ Claim 8 has been amended to delete six (6) species of compounds from the Markush grouping recited therein. Claim 8 is now in proper dependent form, i.e., the subject matter recited therein includes every limitation of claim 1, the claim upon which it depends. No new matter has been added.

In view of the abovementioned amendments and remarks, Applicants respectfully assert that this application is now in condition for allowance. The Examiner is invited to contact the undersigned counsel in order to further the prosecution of this application in any way.

Respectfully submitted,

Date: July 1, 2009

/Edward L. Brant/
Edward L. Brant
Reg. No. 62,362

Fox Rothschild LLP
2000 Market Street, Tenth Floor
Philadelphia, PA 19103
Tel: (215) 299-3830
Fax: (215) 299-2150